Current Headlines

  1. Zealand Pharma Expands Its Peptide Platform With Acquisition Of Encycle Therapeutics
    10/22/2019

    Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the acquisition of Encycle Therapeutics, Inc., a private Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides exhibiting enhanced drug-like properties

  2. Qpex Biopharma And Brii Biosciences Enter Into A Strategic Collaboration To Develop And Commercialize Antibiotics For Drug-Resistant Infections In China
    10/22/2019

    Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that it has entered into a multi-product collaboration with Brii Biosciences to develop and commercialize Qpex's portfolio in China of potentially best-in-class therapies to treat a range of multi-drug resistant gram-negative infections

  3. FDA Grants Orphan Drug Designation For Neuren's NNZ-2591 To Treat Angelman, Phelan-McDermid And Pitt Hopkins Syndromes
    10/17/2019

    Neuren Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome, Phelan-McDermid syndrome and Pitt Hopkins syndrome

  4. Foamix Announces FDA Acceptance Of Its New Drug Application For FMX103 Minocycline Foam For The Treatment Of Moderate-To-Severe Papulopustular Rosacea
    10/17/2019

    Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for FMX103 (minocycline topical foam 1.5%) topical foam. Foamix is seeking approval of FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults

  5. Patient-Derived Tumor Organoid Drug Development Platform Launched
    10/17/2019

    Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery

  6. Augmented Intelligence Company PercayAI Announces Strategic Partnership With Canopy Biosciences® To Help Researchers Accelerate Drug Discovery
    10/17/2019

    PercayAI, a newly launched augmented intelligence software company that helps researchers develop new drugs more quickly and successfully, is announcing its first strategic, commercial partnership with Canopy Biosciences

  7. ViiV Healthcare Submits Supplemental New Drug Application To US FDA For Use Of Dovato In Virologically Suppressed Adults With HIV-1
    10/16/2019

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Dovato (dolutegravir and lamivudine) as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure

  8. BioIVT Acquires PPA Research Group, Increasing Its Ability To Support Drug Development, Cell And Gene Therapy Research
    10/16/2019

    BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired PPA Research Group, Inc., a human hematologic product provider, based in Gray, TN

  9. HitGen Enters Into DNA-Encoded Library Based Drug Discovery Research Collaboration With Galapagos NV
    10/16/2019

    HitGen Inc. recently announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads

  10. Insilico Medicine And ChemDiv Form A Strategic Drug Discovery Service Alliance
    10/16/2019

    Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions